Aug 21 2026 02:09 AM EST

Zoetis Faces Ongoing U.S. Companion Animal Weakness as Competitive and Regulatory Headwinds Persist

Shares of Zoetis Inc. (NYSE: ZTS) have declined nearly 50% over the past year and remain under pressure following a series of guidance cuts and weak quarterly results. The company’s core U.S. companion animal business has contracted sharply, prompting investors to reassess the durability of Zoetis’s growth model as competitive intensity, increased price sensitivity among pet owners, and heightened regulatory scrutiny weigh on near-term prospects.

The central catalyst for Zoetis’s share-price decline has been the sustained weakness in its U.S. companion animal segment, which accounts for roughly 70% of total revenue. In the second quarter of 2026, U.S. companion animal sales contracted 11% year over year to $1.04 billion, driven by lower veterinary clinic traffic, increased price sensitivity among pet owners, and intensified competition—especially in dermatology and parasiticides. The dermatology franchise, including Apoquel and Cytopoint, fell 16% globally, with the U.S. down 18%. Simparica sales remained flat globally but declined in the U.S. due to greater competition and lower clinic visits.

The impact of these trends is evident in Zoetis’s financial results and outlook. Second-quarter revenue was $2.47 billion—essentially flat year over year—and adjusted net income fell 2% to $781 million. Management responded by lowering full-year 2026 guidance for both revenue and earnings, now projecting revenue of $9.12–$9.32 billion and adjusted EPS of $6.15–$6.25, down from previous forecasts of $9.68–$9.96 billion and $6.85–$7.00, respectively. The guidance cut, which followed a similar revision in May, triggered a 21.5% one-day share price drop and reinforced investor concerns over the company’s near-term earnings power.

Competitive and Regulatory Pressures Intensify

The downturn in Zoetis’s U.S. companion animal business reflects both macro and industry-specific pressures. Pet owner price sensitivity has risen as inflation, higher costs, and a normalization in petcare spending patterns prompt pet owners to delay or avoid veterinary visits, particularly for premium therapies. At the same time, rivals such as Elanco and Merck Animal Health have stepped up competitive actions, including increased discounting, rebates, and cross-portfolio bundling in key categories like dermatology and parasiticides. These moves have eroded Zoetis’s market share in historically dominant franchises such as Apoquel, Cytopoint, and Simparica Trio.

Regulatory scrutiny has further complicated the outlook. The FDA has increased post-market safety monitoring for biologic drugs, issuing new safety warnings for Librela and related monoclonal antibody products. These actions have weighed on prescription growth and sentiment for the company’s OA pain portfolio, adding to uncertainty around future revenue streams and potential compliance costs.

Livestock, Diagnostics, and International Segments Provide Offset

Despite the headwinds in companion animal, Zoetis’s livestock and international segments have demonstrated resilience. U.S. livestock revenue surged 23% in the second quarter of 2026, while international sales rose 8% (reported). These gains were supported by favorable producer economics, strong demand for cattle and poultry vaccines, and robust performance in emerging markets. Diagnostics revenue also grew 12% year over year, bolstered by recent acquisitions such as VitalRADS and continued innovation in point-of-care solutions.

However, these positive trends have not been sufficient to offset the scale of contraction in the U.S. companion animal business, which remains the primary driver of Zoetis’s earnings and market valuation. The company’s cost actions—including reductions in SG&A and manufacturing costs—and continued investment in R&D are designed to defend margins and prepare for future growth, but the margin compression from product mix and promotional activity persists.

Pipeline, Strategy, and Valuation Reset

Zoetis continues to invest in a pipeline of more than a dozen potential blockbusters in chronic kidney disease, oncology, cardiology, anxiety, and obesity. Recent launches, such as Lenivia and Portela (long-acting OA pain mAbs), and strategic M&A—including the acquisition of Neogen’s animal genomics business—reflect a focus on innovation and global diversification. Nevertheless, the near-term investment case for the stock is being reassessed, with the shares now trading at 11.6x earnings—well below historical and sector averages.

Analyst price targets and ratings have been reset lower, with the average fair value now $90–$128 per share and consensus shifting to “Moderate Buy.” While some investors, including notable value buyers, have initiated positions on the premise of long-term recovery, most market participants appear to be waiting for stabilization in U.S. trends, resolution of legal and regulatory risks, and further evidence of pipeline execution before revisiting a more constructive stance.

The outlook for Zoetis will depend on its ability to stabilize the U.S. companion animal business, offset pressures through international and livestock growth, and demonstrate clinical and commercial traction with its innovation pipeline. Until visibility on these variables improves, sentiment and valuation are likely to remain subdued, with the next several quarters expected to be pivotal for restoring investor confidence.